摘要随着检测技术灵敏度的不断提高，循环肿瘤DNA（ctDNA）检测的应用领域逐渐从晚期肿瘤拓展到早期肿瘤。近期，ctDNA在实体瘤微小残留病（MRD）检测中的应用尤其受到关注。MRD检测在实体瘤复发风险评估以及治疗指导方面都展现出了重要的意义。然而，各研究中采用的MRD检测策略有所不同，得出的结论也有所差异。本文回顾了ctDNA在实体瘤MRD检测领域的研究进展，阐述了MRD检测技术及应用方面的挑战，旨在推动ctDNA在实体瘤MRD检测中的临床转化与规范应用。

abstractsWith the improvement of detective sensitivity, the application of circulating tumor DNA (ctDNA) has gradually expanded from advanced tumors to early stage. Recently, the detection of minimal residual disease (MRD) using ctDNA in solid tumors has attracted particular attention. MRD testing has shown an essential role in the risk assessment of solid tumor recurrence and treatment guidance. However, the MRD detection strategies used in each study are different, and the conclusions drawn as well. This paper reviewed the research progress of ctDNA for MRD detection in solid tumor, as well as its challenges of detection technology and application, in order to promote the clinical transformation and standardized application of MRD detection by ctDNA in solid tumors.